DENNIS JACKMAN

H.R. 4724--The Medicare IVIG Access Enhancement Act--Lobbied in support of this legislation that would create a home infusion benefit under Medicare Part B for IVIG when used in the treatment of CIDP. Preserving Access to Orphan Drugs Act--Exploration of fine tuning orphan drug exclusion from the annual pharmaceutical fee Educating congressional staff specific to the value of drug therapies (drug pricing, value, access to therapies, etc.) as part of Administration drug pricing blueprint and request for information.

H.R. 3178--Medicare Part B Improvement Act of 2017--Home infusion provision for DME administered drugs incorporated within the budget deal Preserving Access to Orphan Therapies Act--Exploration of fine tuning orphan drug exclusion from the annual pharmaceutical fee Educating congressional staff specific to the value of drug therapies (drug pricing, value, access to therapies, etc.)

Preservation of the orphan drug tax credit opposition of the border adjustment tax/import taxes corporate tax reform preservation of deductibility of interest on debt

Preservation of the orphan drug tax credit opposition of the border adjustment tax corporate tax reform preservation of deductibility of interest on debt

Preservation of the orphan drug tax credit Tax reform

Preservation of the orphan drug tax credit due to the benefit in developing therapies for those with rare diseases. Patient protections regarding health care legislation.

Preservation of the orphan drug tax credit Border adjustment tax as part of tax reform

Preservation of the orphan drug tax credit due to the benefit in developing therapies for those with rare diseases.

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit

Orphan drug exclusion from the branded annual pharmaceutical fee Medicare product access 21st Century Cures legislation

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit

Orphan drug exclusion from the branded annual pharmaceutical fee Medicare product access Appropriations report language specific to NIH

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit Appropriations report language specific to NIH

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit Appropriations report language specific to NIH

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit Appropriations report language specific to NIH

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit Appropriations report language specific to NIH

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit Appropriations report language specific to NIH

Orphan drug exclusion from the branded annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit

Orphan drug exclusion from the annual pharmaceutical fee Preservation of the Orphan Drug Tax Credit as part of any tax reform package

Preserving Access to Orphan Drugs Act (HR 2315/S1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit

Preserving Access to Orphan Drugs Act (HR 2315/S.1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit

Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit

Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit

Preserving Access to Orphan Drugs Act (HR 2315/S.1128) Orphan Drug Tax Credit - highlighting its importance in orphan product development for treatment of rare diseases

Orphan Product Tax issues - Advocating for the Preserving Access to Orphan Drugs Act. Advocating for preservation of the orphan drug tax credit.

Orphan Drug Product issues - annual branded pharmaceutical fee; preservation of the orphan drug tax credit; access to rare disease therapies

Affordable Care Act Issues - annual branded pharmaceutical fee 340B Public Health Service Pricing Program

Affordable Care Act, Annual Pharmaceutical Fee

Affordable Care Act - Annual Pharmaceutical Fee and Medical Device Tax

Affordable Care Act - Annual Pharmaceutical Fee FDA Orphan drug designation requirement and tax credit

Affordable Care Act - Annual Pharmaceutical Fee FDA Orphan designation requirements

Affordable Care Act - Annual Pharmaceutical Fee FDA Orphan designation requirements

Implementation and revision of the orphan drug exception from the annual branded pharmaceutical fee which was enacted in the Affordable Care Act

Implementation of the orphan drug exception from pharmaceutical fee.

Implementation of the orphan drug exception from pharmaceutical fee.

Implementation of the orphan drug exception from pharmaceutical fee.

Implementation of the orphan drug exception from pharmaceutical fee.

Implementation of the orphan drug exception from pharmaceutical fee.

Implementation of the orphan drug exception from pharmaceutical fee.

Implementation of the orphan drug exception from pharmaceutical fee.

Implementation of the orphan drug exception from pharmaceutical fee.

Implementation of the orphan drug exception from the annual pharmaceutical fee as specified in the Affordable Care Act.

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701); H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701); H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Part B and hospital reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage.

Medicare Part B and hospital reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage.

Medicare Part B and hospital reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage.

Medicare Part B and hospital reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage.

Medicare Part B and hospital reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage.

Medicare Part B and hospital reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage.

Medicare Part B and hospital reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage.

Medicare Part B and hospital reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage.

Medicare Part B and hospital reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage.

Medicare Part B and Hospital Outpatient reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage

Medicare Part B and hospital outpatient reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage.

Medicare Part B and Hospital Outpatient reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage

Medicare Part B and Hospital Outpatient reimbursement (seeking payment adjustment); elimination of bundled IVIG reimbursement product class; seeking access to Medigap for Medicare beneficiaries with disability so they will have opportunity for secondary insurance coverage